(Q37697779)

22 August 2017

1 reference

title

Genetic causes of clopidogrel nonresponsiveness: which ones really count? (English)

1 reference

22 August 2017

1 reference

2

Michael P Dorsch

1 reference

22 August 2017

Kathryn M Momary

1

1 reference

PubMed ID

20180610

22 August 2017

Eric R Bates

series ordinal

3

1 reference

PubMed ID

20180610

22 August 2017

language of work or name

English

0 references

publication date

1 March 2010

1 reference

22 August 2017

1 reference

22 August 2017

30

1 reference

22 August 2017

3

1 reference

22 August 2017

265-274

1 reference

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

22 August 2017

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Platelet function monitoring in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Bedside evaluation of thienopyridine antiplatelet therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Variability in platelet aggregation following sustained aspirin and clopidogrel treatment in patients with coronary heart disease and influence of the 807 C/T polymorphism of the glycoprotein Ia gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Clinical significance of the cytochrome P450 2C19 genetic polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Molecular basis of ethnic differences in drug disposition and response

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel: a possible mechanism for clopidogrel resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Cytochrome p-450 polymorphisms and response to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Genetic determinants of response to clopidogrel and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Effect of cytochrome p450 polymorphisms on platelet reactivity after treatment with clopidogrel in acute coronary syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

The role of P-glycoprotein and organic anion-transporting polypeptides in drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Point-of-care platelet function analysis ready for prime time?

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

Prasugrel versus clopidogrel in patients with acute coronary syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.30.3.265

21 January 2018

Identifiers

DOI

10.1592/PHCO.30.3.265

1 reference

22 August 2017

1 reference

PubMed ID

20180610